US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
biotech · Relapsed or Refractory Multiple Myeloma
Wuhan YZY Biopharma
Wuhan YZY Biopharma Co.,
Wuhan YZY Biopharma drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Wuhan, CN HQ
2010 Founded
55 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Wuhan, CN
- Founded
- 2010
- Employees
- 55
- Programs
- 1
- Drugs
- 2
- Patents
- 0
Wuhan YZY Biopharma pipeline
Portfolio lens on 2 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Wuhan YZY Biopharma drug portfolio — 2 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Wuhan YZY Biopharma in public FDA and regional records.